A combination of the standard-of-care chemotherapy
drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid
leukemia (AML) according to findings.